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SATORU TODO, ALLAN L. DRASH, AND THOMAS E. STARZL 
From days 30-120 after birth, 59 BB rats were treated 
with water (n = 20) or FK 506 in intra gastric doses of 
1 mg' kg- 1 • day-l (n = 19) or 2 mg . kg- 1 'day-l (n = 
20). Diabetes developed in 75, 15, and 0% of th~ 3 
groups, respectively. Animals protected from diabetes 
by FK 506 had normal intraperitoneal glucose 
tolerance tests, virtual absence histopathologically of 
autoimmune insulltis, and normal pancreatic insulin 
content. Forty-five to 75 days after stopping FK 506, 
-75% of the rats that were diabetes free at 120 days 
remained so. Diabetes 39:1584-86, 1990 
The demonstration that cyclosporin A (CsA) could prevent autoimmune BB rat diabetes (1-3) led to 
clinical trials with this drug in patients with recent-
onset insulin-dependent diabetes (4-6). Remis-
sions were often accomplished if CsA was given soon 
enough and in adequate doses but at the cost of drug neph-
rotoxicity (4-6). FK 506, another potent immunosuppressive 
agent that is undergoing trials in transplantation (7), is chem-
ically unrelated to CsA but also suppresses T-Iymphocyte 
activation by inhibiting the transcription of mRNAs for early-
phase Iymphokines, i.e., interleukin (IL) 2, IL-3, and inter-
feron-'Y (8). 
RESEARCH DESIGN AND METHODS 
We examined the influence of daily enteral FK 506 given 
between ages 30 and 120 days on BB rat diabetes. We 
established the following experimental groups: group 1 
(n = 20) was given only tap water, group 2 (n = 19) was 
given 1 mg . kg- 1 • day-l FK 506, and group 3 (n = 20) 
was given 2 mg . kg- 1 • day-l FK 506. The FK 506 doses 
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were extrapolated from earlier dose-efficacy studies and 
were estimated to be V4- Va of those optimal for induction of 
long-lasting allograft acceptance (9) The 59 rats were ob-
tained from seven consecutive litters, randomly deployed to 
the three sex-matched groups, raised under controlled light-
ing, and allowed tap water and regular rat food. Tap water 
or FK 506 was given by daily gastric intubation. FK 506 
(Fujisawa, Osaka, Japan) was dispersed with hydroxypropyl 
methylcellulose and diluted in tap water by sonication. Onset 
of diabetes was diagnosed by glycosuria (tested 3 times/ 
wk) and confirmed by nonfasted blood glucose >11.1 mM 
from tail vein samples for 3 consecutive days. 
RESULTS 
During the 90-day treatment, diabetes developed in 75, 15.7, 
and 0% of tap water, low-dose FK 506, and high-dose FK 
506 groups, respectively (Fig. 1), There was no mortality and 
very little inhibition (NS) of weight gain of the nondiabetic 
rats in the treatment groups (Fig, 2). The protective effect of 
FK 506 often outlasted the time of treatment (Table 1). Only 
five rats subsequently became diabetic (3 associated with 
pregnancy). 
Glucose intolerance was not observed with the doses of 
FK 506 used in this study. In the nondiabetic control rats 
and the FK 506-protected rats. blood glucose levels ob-
tained every 2 wk were normal (Fig. 3). Three rats from group 
2 and 6 rats from group 3 had normal intraperitoneal glucose 
tolerance tests (2 g glucose/kg body wt) before they were 
killed for tissues on the last day of treatment (Fig. 4). 
Other blood chemistry measurements and pancreatic in-
sulin content were determined at the end of the FK 506 
treatment in six of the nondiabetic survivors killed in group 
2 and five of those killed in group 3. There was no increase 
of blood urea nitrogen, creatinine, glutamic-oxaloacetic 
transaminase, or glutamic-pyruvic transaminase compared 
with six nondiabetic Wistar-Furth (non-BB) rats (Table 2), The 
livers and kidneys were normal histopathologically. At death, 
pancreatic tail tissue was diced into small pieces in cold 
acid-ethanol (75.2% absolute ethanol, 1.4% hydrochloric 
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FIG. 1. Onset and incidence of diabetes under treatment with 1 
mg· kg- 1 • day-' oral FK 506 (A, 3 of 19 developed diabetes), 2 
mg· kg-' . day-' FK 506 (.,0 of 20 developed diabetes), or water (e, 15 of 20 developed diabetes) from 30 to 120 days of age. 
acid, and 23.4% distilled H20) and sonicated vigorously for 
10 min at 4°C. After centrifugation at 500 rpm for 10 min, the 
supernatant fractions were frozen for subsequent assays of 
insulin by radioimmunoassay. Pancreatic insulin content in 
these rats was normal (Table 2). Histopathologically, these 
pancreases were free of the insulitis and periductular inflam-
mation that was invariable in the untreated diabetic rats. 
In additional analyses, immunocytochemical studies were 
performed on tissue sections from rats in groups 1-3 and 
four nondiabetic Wistar-Furth controls. Guinea pig anti-hu-
man insulin antibodies (Biogenex, San Ramon, CAl and 
rabbit anti-human glucagon antibodies (Amersham, Ayles-
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FIG. 2. Effect of FK 506 treatment on body weight in males (L'I, 1 
mg· kg-' . day-'; 0, 2 mg . kg-' . day-') and females (A, 1 mg . 
kg-' . day-'; e, 2 mg . kg-' . day-') compared with their male and 
female water-treated siblings (0 and ., respectively). Only 5 water-
treated rats were nondiabetic at 120 days. 
bury, UK) have sufficient cross-reactivity with the respective 
rat hormones to allow immunohistochemical detection. Lo-
calization of these antibodies onto fixed paraffin-embedded 
tissues was visualized with the avidin-biotin procedure (Vec-
tor, Burlingame, CAl. Color was developed with 3-amino-
9-ethylcarbazole (Biomeda, Foster City, CAl The entire 
procedure was performed on a computer-driven robot 
(Code-On, Fisher, Pittsburgh, PAl, which allowed the place-
ment of parallel control slides. In nondiabetic Wistar-Furth 
rats, insulin-containing cells were clearly demarcated and 
generally inhabited the centers of the islets. Glucagon-con-
Fate after 120 days of rats treated with FK 506 from days 30-120 of age 
Survival 2:120 days without diabetes 
Killed at 120 days 
Animals remaining >120 days 
Survival 2:150 days without diabetes 
Killed at 150 days 
Animals remaining >150 days 
Survival 165-195 days without diabetes 
*Two other rats became diabetic at 132 and 147 days. 
Control 
5 of 20 
2 of 5 
3 
3 
3 of 3 
1 mg . kg .. day-' 
16 of 19 
6 of 16 
10 
8* 
2 of 8 
6 
6 
FK 506 treated 
tThree other rats were used for breeding and became diabetic while pregnant at 170,175, and 180 days. 
TABLE 2 
Blood chemistry and pancreatic insulin content at 120 days of age in 3 groups of rats 
Groups 
FK 506 
1 mg· kg-' . day-1 
2 mg . kg- 1 . day-' 
Control 
n 
6 
5 
6 
BUN 
(mM) 
86 ± 2.5 
10.6 ± 1.9 
8.3 ± 1.5 
Creatinine GOT 
(ILM) (U/L) 
70.7 ± 17.7 130.3 ± 93.0 
88.4 ± 35.4 134.6 ± 69.1 
70.7 ± 8.8 123.2 ± 19.2 
GPT 
(U/L) 
33.8 ± 9.3 
35.0 ± 9.4 
363 ± 2.9 
2 mg . kg -, . day 1 
20 of 20 
6 of 20 
14 
14 
2 of 14 
12 
9t 
Insulin content 
(pmol/mg 
pancreas) 
32.4 ± 21.0 
16.2 ± 14.4 
19.2 ± 3.6 
Values are means ± SD. BUN, blood urea nitrogen; GOT, glutamic-oxaloacetic transaminase; GPT, glutamic-pyruvic transaminase. 
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FIG. 3 Blood glucose levels at 30-120 days of age in nondiabetic 
survivors during FK 506 treatment (0, 1 mg· kg-I. day-I, n = 16; D, 
2 mg' kg-I. day-" n = 20) compared with water treatment (A, n = 5). 
taining cells formed a distinct peripheral rim around the is-
lets. With the development of diabetes in the untreated BB 
rats, insulin-containing cells disappeared completely, islet 
size was reduced. and the cells stained only with anti-glu-
cagon antibodies. In contrast, normal-appearing distribu-
tions of insulin- and glucagon-containing cells were ob-
served in 5 of 6 low-dose FK 506 and 3 of 3 high-dose FK 
506 rats. 
DISCUSSION 
These data together with other observations support the no-
tion that FK 506 may be a successful immune intervention 
agent for recent-onset diabetes. The therapeutic index of FK 
506 in humans is better than CsA (7,10), even though it is 
expected to have a qualitatively similar toxicity profile, in-
cluding diabetogenic, neurotoxic, and nephrotoxic potential. 
Although the drugs are chemically unrelated, the central 
action of both is speculated to be inhibition of the enzyme 
peptidylprolyl isomerase (PPlase), which is the principal con-
stituent of their cytosolic binding sites. The ubiquitous dis-
tribution of PPlase, including kidney and pancreas, implies 
that drugs that modulate it will affect multiple nonimmu-
nologic metabolic processes (11). However, evidence is 
mounting that these consequences will not vitiate the value 
of FK 506 in transplantation or for the treatment of autoim-
mune diseases (7,10,11). 
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FIG. 4. Blood glucose levels during intraperitoneal glucose tolerance 
test before death on day 120 in BB rats treated with oral FK 506 (0, 1 
mg' kg-I. day-" n = 3; D, 2 mg . kg-I. day-" n = 6) compared with 
nondiabetic Wistar-Furth (non-BB) rats (A, n = 3). Glucose (2 9 Ikg) 
was administered at 0 min. 
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